|
05/11/2024
|
07:00
|
Shareholders’ Nomination Board
|
RNS
|
|
22/10/2024
|
07:00
|
Faron’s Capital Markets Day 2024
|
RNS
|
|
30/08/2024
|
07:00
|
Grant of options
|
RNS
|
|
27/08/2024
|
07:00
|
Faron 2024 Half-Year Financial Results
|
RNS
|
|
27/08/2024
|
07:00
|
FDA Grants Fast Track Designation for Bexmarilimab
|
RNS
|
|
20/08/2024
|
07:00
|
Notice of Half-Year Financial Results
|
RNS
|
|
08/08/2024
|
07:00
|
Appointment of Chief Financial Officer
|
RNS
|
|
07/08/2024
|
10:00
|
Grant of options
|
RNS
|
|
06/08/2024
|
08:30
|
Faron Appoints Dr. Petri Bono as new CMO
|
RNS
|
|
11/07/2024
|
07:00
|
Faron Announces Positive FDA Feedback
|
RNS
|
|
25/06/2024
|
14:00
|
Update on settlement
|
RNS
|
|
25/06/2024
|
10:30
|
Holding(s) in Company - Replacement
|
RNS
|
|
24/06/2024
|
12:45
|
Holding(s) in Company
|
RNS
|
|
24/06/2024
|
12:45
|
Holding(s) in Company
|
RNS
|
|
24/06/2024
|
12:45
|
Holding(s) in Company
|
RNS
|
|
24/06/2024
|
12:45
|
Holding(s) in Company
|
RNS
|
|
20/06/2024
|
13:00
|
New shares registered with Finnish Trade Register
|
RNS
|
|
20/06/2024
|
07:00
|
Fully subscribed EUR 30.7 million share offering
|
RNS
|
|
05/06/2024
|
08:00
|
Proposed REX Retail Offer
|
RNS
|
|
04/06/2024
|
07:00
|
Faron commences a share offering
|
RNS
|
|
20/05/2024
|
07:00
|
Initial positive data from Phase 2 of BEXMAB
|
RNS
|
|
17/05/2024
|
16:00
|
Issuance of warrants
|
RNS
|
|
13/05/2024
|
07:00
|
Replacement – Board Change
|
RNS
|
|
30/04/2024
|
14:00
|
Update on financial status
|
RNS
|
|
30/04/2024
|
13:00
|
Board Change
|
RNS
|
|
15/04/2024
|
07:00
|
Appointment of Chief Financial Officer
|
RNS
|
|
08/04/2024
|
07:10
|
Approval of Warrant Terms and Conditions
|
RNS
|
|
08/04/2024
|
07:05
|
Decisions of the Board of Directors
|
RNS
|
|
08/04/2024
|
07:00
|
Appointment of Chief Executive Officer
|
RNS
|
|
05/04/2024
|
12:00
|
Results of the Annual General Meeting
|
RNS
|
|
04/04/2024
|
07:00
|
Announcement of Placing
|
RNS
|
|
28/03/2024
|
07:00
|
Issue of Warrants to IPF Funding Update
|
RNS
|
|
26/03/2024
|
10:00
|
Faron´s Annual Report 2023
|
RNS
|
|
18/03/2024
|
07:00
|
Additional Positive Data from Phase 1 of BEXMAB
|
RNS
|
|
13/03/2024
|
14:00
|
Notice of Annual General Meeting 2024
|
RNS
|
|
13/03/2024
|
07:00
|
Financial Statement January 1 to December 31 2023
|
RNS
|
|
04/03/2024
|
07:00
|
Binding commitments for convertible loans
|
RNS
|
|
28/02/2024
|
16:00
|
Replacement - Update to 2024 Financial Calendar
|
RNS
|
|
27/02/2024
|
18:00
|
Update to Faron’s Financial Calendar for 2024
|
RNS
|
|
21/02/2024
|
14:00
|
Continued Negotiations Regarding Events of Default
|
RNS
|
|
19/02/2024
|
10:30
|
Events of Default
|
RNS
|
|
31/01/2024
|
07:00
|
Further re: Exercise of options
|
RNS
|
|
25/01/2024
|
07:00
|
BEXMAB Insights into Patient Profiles
|
RNS
|
|
19/01/2024
|
13:00
|
Exercise of options - Issue of equity
|
RNS
|
|
09/01/2024
|
07:00
|
First Patient Dosed in Ph 2 of the BEXMAB Trial
|
RNS
|
|
22/12/2023
|
07:00
|
Faron’s Financial Calendar for 2024
|
RNS
|
|
11/12/2023
|
07:00
|
Phase 1 BEXMAB data presented at ASH
|
RNS
|
|
04/12/2023
|
07:00
|
Grant of options
|
RNS
|
|
06/11/2023
|
08:13
|
Faron Initiates Phase 2 Part of BEXMAB Study
|
RNS
|
|
06/11/2023
|
07:00
|
Faron Initiates Phase 2 Part of BEXMAB Study
|
RNS
|